论文部分内容阅读
1977年至1995年我科应用丙酸倍氯松气雾剂(BDP)防治小儿哮喘千余名,平均剂量为300μg·d,疗程2.16±1.52年。对其中399例患儿进行了长期随访,考核临床疗效,并行肺功能、气道高反应性、外周血淋巴细胞CD23表达、肾上腺皮质功能、咽部霉菌和身高体重的测定。结果显示:临床有效率达84.21％,对照组为24.39％(P<0.01),早晚PEF显著增加。气道高反应性下降,外周血淋巴细胞CD23阳性率降低,血浆皮质醇、ACTH含量与身高、体重均在正常值范围内。我们总结了4项措施使其疗效高达98％。本文显示长期吸入BDP可使哮喘得到理想控制,并可降低气道高反应性而无全身副作用。
1977-1995 Division I use beclomethasone propionate aerosol (BDP) prevention and treatment of more than a dozen children with asthma, the average dose of 300μg · d, treatment 2.16 ± 1. 52 years. Long-term follow-up of 399 children was performed to evaluate the clinical efficacy and pulmonary function, airway hyperresponsiveness, CD23 expression in peripheral blood lymphocytes, adrenocortical function, pharyngeal mold and height and body weight. The results showed that: the clinical effective rate was 84.21%, control group was 24.39% (P <0.01), PEF increased significantly. Airway hyperresponsiveness decreased, the positive rate of CD23 in peripheral blood lymphocytes decreased, plasma Cortisol, ACTH content and height, weight were in the normal range. We have summarized 4 measures to make it 98% effective. This article shows that long-term inhalation of BDP provides optimal control of asthma and reduces airway hyperresponsiveness without systemic side effects.